Crossmark

Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons

Crossref DOI link: https://doi.org/10.1186/s13063-019-3322-7

Published Online: 2019-05-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Hague, Dominic https://orcid.org/0000-0002-2699-7799
Townsend, Stephen https://orcid.org/0000-0002-9049-6999
Masters, Lindsey https://orcid.org/0000-0002-1587-8065
Rauchenberger, Mary https://orcid.org/0000-0002-7304-8270
Van Looy, Nadine

Diaz-Montana, Carlos https://orcid.org/0000-0001-9082-4596
Gannon, Melissa https://orcid.org/0000-0002-9163-0571
James, Nicholas https://orcid.org/0000-0002-7314-8204
Maughan, Tim

Parmar, Mahesh K. B. https://orcid.org/0000-0003-0166-1700
Brown, Louise https://orcid.org/0000-0003-2827-6634
Sydes, Matthew R. https://orcid.org/0000-0002-9323-1371
Funding

Funding for this research was provided by:

Efficacy and Mechanism Evaluation Programme (11/100/50)

Cancer Research UK (A13363)

Cancer Research UK (162082)

Medical Research Council (171339)

Sanofi

Novartis Pharmaceuticals UK Limited (158519)

Janssen Pharmaceuticals (163301)

Astellas Pharma Europe (163026)

AstraZeneca Schweiz (158046)
License Information

Text and Data Mining valid from 2019-05-29

Version of Record valid from 2019-05-29
More Information

Article History

Received: 10 August 2018

Accepted: 25 March 2019

First Online: 29 May 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: DH, ST, LM, MR, NVL, CDM, MP, LB and MRS are all employed by the Medical Research Council, a publicly funded body in the United Kingdom that is sponsoring both trials. The other author(s) declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below